Clinical Trial Update: Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating safety and tolerability of TNG908 in MTAP-deleted solid tumors has been terminated. The sponsor is Tango Therapeutics.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• TNG908

Snippet

Sponsor: Tango Therapeutics, Inc. | Conditions: Locally Advanced Solid Tumor | Phase 1, Phase 2 | Status: TERMINATED